obinutuzumab & rituximab safety risks
Published 5 years ago • 2.5K plays • Length 3:18Download video MP4
Download video MP3
Similar videos
-
1:32
deciding on rituximab versus obinutuzumab in follicular lymphoma
-
4:38
an in-depth look at treatment of follicular lymphoma
-
5:17
follicular lymphoma: selecting frontline therapy
-
3:53
the safety and efficacy of venetoclax/obinutuzumab combo in cll
-
4:36
obinutuzumab versus rituximab in frontline fl
-
4:29
venetoclax with rituximab treatment and safety profile
-
8:07
obinutuzumab plus bendamustine in rituximab-refractory indolent non-hodgkin lymphoma
-
40:12
monoclonal antibodies – rituximab & obinutuzumab | rebecca beck, lymphoma australia
-
4:13
venetoclax/rituximab administration & toxicity management
-
2:02
the monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target cd20...
-
2:53
follicular lymphoma: obinutuzumab and chemotherapy
-
4:07
rituximab, obinutuzumab, and ofatumumab in cll
-
6:30
fl: switching to bendamustine/rituximab at progression
-
4:34
obinutuzumab bests rituximab for pfs in follicular lymphoma
-
21:17
new anti-cd20 antibodies for cll - are they better than rituximab?
-
5:06
approaching a case of high-risk follicular lymphoma
-
5:40
appropriately diagnosing and classifying mzl
-
3:41
comorbidities and rituximab-based therapy in fl
-
3:43
cll: clinical data for rituximab/venetoclax